Navigation Links
ViewRay Demonstrates Potential Therapy Applications for MRI-Guided Radiation at ASTRO 2011

CLEVELAND, Sept. 29, 2011 /PRNewswire/ -- ViewRay™, Inc., a privately held medical device company, will present potential applications for MRI-guided radiotherapy at the annual meeting of the American Society for Radiation Oncology (ASTRO) October 2 – 4 in Miami Beach, Florida, with software demonstrations in booth #865. The company's new research radiation therapy system is being developed to feature a patented combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI). The system is being designed to let radiation oncologists see what they're treating, while they're treating.

Visitors to ViewRay's ASTRO booth can view software demonstrations and learn about the key capabilities being designed into the system. In addition to quality pretreatment imaging and advanced treatment delivery, the ViewRay system is being developed to enable:

  • On-table dose prediction — fast dose prediction using volumetric image data captured just prior to treatment.
  • Soft-tissue targeting — continuous, MRI-guided tracking of soft tissues and automatic beam control for real-time adaptation to motion.
  • Adaptive optimization — fast, convenient reoptimization for effective online and offline plan adaptation.
  • Review and assessment — software tools that help physicians better understand and manage the progress of treatment.

ViewRay holds the exclusive worldwide license for its combination of MRI and radiation therapy technologies. Earlier this year, landmark patents were issued for ViewRay's core technology in both the United States and Europe. ViewRay's treatment planning and delivery software recently received 510(k) premarket notification clearance from the U.S. FDA, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review. The ViewRay system is currently available only as a non–human use research system.

"With the 510(k) clearance of our software, the issuance of patents on our technology, and the addition of several new research partners, we've reached major milestones this year," said ViewRay President and CEO Gregory M. Ayers, MD, PhD. "We're looking forward to sharing our progress with the ASTRO community." ViewRay research partners now include the University of California, Los Angeles (UCLA) Health System – Jonsson Comprehensive Cancer Center, the University of Wisconsin Carbone Cancer Center, and the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine, where the first ViewRay research system is currently being installed.

About ViewRay

ViewRay, Inc., of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system is being designed to provide continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

ViewRay is a trademark of ViewRay, Inc.

SOURCE ViewRay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViewRay Wins NorTech Innovation Award
2. Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System
3. ViewRay Secures Series C Financing
4. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
5. University of Wisconsin Carbone Cancer Center to Acquire ViewRay Radiation Therapy System
6. Landmark Patents Issued for ViewRay Technology
7. UCLA Health System - Jonsson Comprehensive Cancer Center to Acquire ViewRay Radiation Therapy Research System
8. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
9. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/25/2015)... ... , ... The holiday season is jam-packed with family dinners, ... attendees is of the utmost importance. Whether you are cooking at home for ... a try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of ... patients are aware of the benefits of Botox® in the treatment of moderate facial ... discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, ...
Breaking Medicine News(10 mins):